SCHEMBL1900720

SCHEMBL1900720

NC(=O)CCN1CCNCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.63
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HSD17B10 Q99714 1/20 0.41
CXCR4 P61073 2/20 0.41
ANPEP P15144 1/20 0.40
ERAP2 Q6P179 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CHRM5 P08912 2/20 0.39
CHRM3 P20309 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
SIGMAR1 Q99720 2/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8742997 0.98 L3MBTL1 (0.61) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL613914 0.89 L3MBTL1 (0.50) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL28706410 0.88 L3MBTL1 (0.48) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL1076280 0.88 CXCR4 (0.50) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL28716335 0.88 L3MBTL1 (0.48) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL15743490 0.86 CXCR4 (0.53) L3MBTL1POLBSMN1; SMN2CXCR4CHRM5
SCHEMBL8859810 0.84 L3MBTL1 (0.46) L3MBTL1POLBSMN1; SMN2HSD17B10CXCR4
SCHEMBL8860545 0.84 L3MBTL1 (0.77) L3MBTL1POLBSMN1; SMN2KMT2AMAPT
SCHEMBL11598668 0.84 L3MBTL1 (0.77) L3MBTL1POLBSMN1; SMN2KMT2AMAPT
Tert-Butyl Formate SCHEMBL28278570 0.82 L3MBTL1 (0.45) L3MBTL1SMN1; SMN2ANPEPERAP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405343-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-07-31 EP claimed
CN-118307525-A Iridoid compound, preparation method thereof, pharmaceutical composition and application thereof 安徽中医药大学 2024-07-09 CN claimed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN claimed
CN-116096719-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-09 CN claimed
WO-2023046698-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-03-30 WO claimed
CN-103130774-A Compound with tyrosine kinase inhibition effect and preparation method and application thereof QILU PHARMACEUTICAL CO LTD 2013-06-05 CN claimed
US-20100063049-A1 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2010-03-11 US claimed
CN-101454312-A 2-Carbocyclic amino-4-imidazolyl pyrimidines as inhibitors of cell proliferation ASTRAZENECA AB (SE) 2009-06-10 CN claimed
EP-2029578-A1 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-04 EP claimed
WO-2007138277-A1 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 WO claimed
WO-2025125302-A1 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-06-19 WO disclosed
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 EP disclosed
CN-118307525-A Iridoid compound, preparation method thereof, pharmaceutical composition and application thereof 安徽中医药大学 2024-07-09 CN disclosed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN disclosed
EP-4182322-B1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-04-24 EP disclosed
WO-1997030034-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ZENECA LIMITED (GB) 1997-08-21 WO disclosed
WO-1997030044-A1 QUINAZOLINE COMPOUNDS ZENECA LIMITED (GB) 1997-08-21 WO disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 WO disclosed
US-4678788-A N-substituted 2-chloro-7-fluoro-10-piperazino-10,11-dihydrodibenzo (B,F) thiepins and acid addition salts thereof SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) 1987-07-07 US disclosed
EP-0189310-A2 N-Substituted 2-chloro-7-fluoro-10-piperazino-10,11-dihydrodibenzo (b,f) thiepins, their acid addition salts and processes for the preparation thereof SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) 1986-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063049-A1 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION MKI67, CCNI, CDK2 L3MBTL1 3470/4885POLB 130/4885SMN1; SMN2 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.